GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc has welcomed today’s jury verdict in the Joiner case in Illinois state court finding in GSK’s favour.

·   Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer

·   Verdict is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

·   GSK will continue to vigorously defend itself against all other claims

This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims.

Prior to this verdict, the court rejected the Plaintiff’s ability to request punitive damages.